The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy.
gastric cancer
lymph node ratio
neoadjuvdnt
prognostic
staging
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
22 Apr 2021
22 Apr 2021
Historique:
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
29
5
2021
Statut:
epublish
Résumé
Objective In this study, we aimed to investigate the prognostic value of postoperative lymph node ratio (LNR)in locally advanced gastric cancer (GC) patients receiving neoadjuvant chemotherapy (NACT). Methods LNR was calculated as the ratio of positive LNs to the total LNs removed. The receiver operating characteristic (ROC) curve was plotted to estimate the cut-off value of LNR for recurrence. The area under the curve of LNR was 0.714 (95% CI: 0.604-0.825, p<0.001) with 60% sensitivity and >0.255 with 76% specificity. Patients were grouped as group I (≤0.255) and group II (>0.255). Results In this study, 157 GC patients were included (39.5% female and 60.5% male). Of the patients, 97 (61.8%) were in group I and 60 (38.2%) were in group II. Disease‑free survival (DFS) was not reached in group I, and it was 16 months in group II (p<0.001). Overall survival (OS) was 58 months in group I and 28 months in group II (p>0.001). In multivariate analysis, lymphovascular invasion, neoadjuvant response, adjuvant treatment, and LNR were found to be the factors associated with DFS and OS (p<0.05). Conclusion In our study, it was observed that LNR can predict survival rates better than LN staging.
Identifiants
pubmed: 34046274
doi: 10.7759/cureus.14639
pmc: PMC8140955
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e14639Informations de copyright
Copyright © 2021, Sakin et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Surg Oncol. 2015 Jun;24(2):84-8
pubmed: 25912951
Eur J Cancer. 1999 Jul;35(7):1059-64
pubmed: 10533448
Am J Clin Oncol. 2013 Aug;36(4):325-30
pubmed: 22547011
Ann Surg. 2015 Dec;262(6):991-8
pubmed: 25563867
Ann Surg Oncol. 2019 Oct;26(11):3602-3610
pubmed: 31350645
J Clin Oncol. 2005 Oct 1;23(28):7114-24
pubmed: 16192595
Lancet. 1996 Apr 13;347(9007):995-9
pubmed: 8606613
J Clin Oncol. 2004 Jul 15;22(14):2774-80
pubmed: 15254045
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am Surg. 2007 Apr;73(4):359-66
pubmed: 17439029
J Surg Oncol. 2018 Jun;117(8):1721-1728
pubmed: 29949666
Medicine (Baltimore). 2016 Apr;95(16):e3395
pubmed: 27100426
Gastric Cancer. 2017 Mar;20(2):217-225
pubmed: 26897166
World J Surg Oncol. 2020 Oct 8;18(1):262
pubmed: 33032609
Thorac Cancer. 2020 Dec;11(12):3490-3500
pubmed: 33034409
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Oct 25;21(10):1148-1153
pubmed: 30370514
N Engl J Med. 1995 Jul 6;333(1):32-41
pubmed: 7776992
Cancers (Basel). 2019 Dec 01;11(12):
pubmed: 31805755
Radiat Oncol. 2020 Oct 14;15(1):237
pubmed: 33054848
Eur J Breast Health. 2020 Jul 29;16(4):270-275
pubmed: 33062968
J Surg Oncol. 2007 Jul 1;96(1):14-8
pubmed: 17582596
J Clin Oncol. 2016 Aug 10;34(23):2721-7
pubmed: 27298411
Gastric Cancer. 2012 Sep;15 Suppl 1:S70-88
pubmed: 22895615
Ann Surg Oncol. 2019 Oct;26(11):3618-3626
pubmed: 31222685
Ann Surg. 2007 Apr;245(4):543-52
pubmed: 17414602
Gastric Cancer. 2013 Jul;16(3):309-17
pubmed: 22945599
Ann Surg. 1993 Jul;218(1):47-53
pubmed: 8328829
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
Cochrane Database Syst Rev. 2013 May 31;(5):CD008107
pubmed: 23728671
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Int J Surg. 2018 Sep;57:76-83
pubmed: 30103072
Surg Today. 2018 Nov;48(11):994-1003
pubmed: 29926189
Jpn J Surg. 1981 Mar;11(2):127-39
pubmed: 7300058
Ann Surg. 1993 Nov;218(5):583-92
pubmed: 8239772